HOUSTON, Aug. 6, 2019 /PRNewswire/ -- Moleculin Biotech,
Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical
stage pharmaceutical company with a broad portfolio of drug
candidates targeting highly resistant tumors, today announced that
a paper entitled "Immunological Reprogramming in the CNS Tumor
Microenvironment and Therapeutic Efficacy of Radiotherapy with
STAT3 Blockade" will be presented at the Inaugural Conference on
Brain Metastases, in New York
City, August 16-17, 2019.
"As the scientific community is increasingly focused on the
potential of STAT3 inhibition for the treatment of cancer, this is
a very timely discovery," Walter
Klemp, Moleculin's Chairman and CEO, remarked. "Dr.
Martina Ott, of MD Anderson Cancer
Center, will be presenting the findings of research she conducted
in collaboration with Dr. Amy
Heimberger (the Principle Investigator of the current
investigator-initiated clinical of WP1066 for brain tumors) in
combining WP1066 with radiation therapy in glioblastoma animal
models. One of the findings of her research that is
especially encouraging is that immune-competent mice treated with
both radiation and WP1066 developed an immunological memory that
enabled them to prevent regrowth of the tumor after these tumor
cells were reintroduced. The result was the development of
long-term survivors, leading to an increase in overall survival in
these models. Of note was that mice with a compromised immune
system did not show this effect."
Dr. Sandra Silberman, Moleculin's
Chief Medical Officer for New Projects, commented: "Making any kind
of impact in treating glioblastoma is exciting, and we think Dr.
Heimberger's findings will have a profound impact on understanding
the role of STAT3 inhibition, as well as help focus our continued
development of WP1066 in this disease. This study was also
particularly interesting because it showed the most robust
immunological responses were located in the CNS (Central Nervous
System) tumor microenvironment rather than peripheral non-tumor
tissue. Importantly, the study indicated that the combination
of STAT3 inhibition with whole brain radiotherapy had the capacity
to enhance the therapeutic effect against established tumors based
on immunological competence. We're now very eager to explore
this potential in human clinical trials."
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of oncology
drug candidates for the treatment of highly resistant tumors. The
Company's clinical stage drugs are: Annamycin, a Next Generation
Anthracycline, designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity being studied for the treatment of
relapsed or refractory acute myeloid leukemia, more commonly
referred to as AML, WP1066, an Immune/Transcription Modulator
capable of inhibiting p-STAT3 and other oncogenic transcription
factors while also stimulating a natural immune response, targeting
brain tumors, pancreatic cancer and hematologic malignancies, and
WP1220, an analog to WP1066, for the topical treatment of cutaneous
T-cell lymphoma. Moleculin is also engaged in preclinical
development of additional drug candidates, including additional
Immune/Transcription Modulators, as well as compounds capable of
Metabolism/Glycosylation Inhibition.
For more information about the Company, please visit
http://www.moleculin.com.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of WP1066 to show
safety and efficacy in combination with other treatments in humans.
Although Moleculin believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
expectations may prove to have been materially different from the
results expressed or implied by such forward-looking statements.
Moleculin Biotech has attempted to identify forward-looking
statements by terminology including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,''
''approximately'' or other words that convey uncertainty of future
events or outcomes to identify these forward-looking statements.
These statements are only predictions and involve known and unknown
risks, uncertainties, and other factors, including those discussed
under Item 1A. "Risk Factors" in our most recently filed Form 10-K
filed with the Securities and Exchange Commission ("SEC") and
updated from time to time in our Form 10-Q filings and in our other
public filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events. The
Company cautions investors not to place undue reliance on the
pre-clinical findings announced today.
Contacts
Joe Dorame, Robert Blum or Joe
Diaz
Lytham Partners, LLC
602-889-9700
mbrx@lythampartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/moleculin-announces-breakthrough-discovery-wp1066-potentially-capable-of-immune-reprogramming-in-glioblastoma-animal-models-300896621.html
SOURCE Moleculin Biotech, Inc.